Shattuck Labs Inc
$ 4.94
18.18%
12 Jun - close price
- Market Cap 471,810,000 USD
- Current Price $ 4.94
- High / Low $ 5.04 / 4.47
- Stock P/E N/A
- Book Value 1.27
- EPS -0.56
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.61 %
- 52 Week High 8.33
- 52 Week Low 0.71
About
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is headquartered in Austin, Texas.
Analyst Target Price
$14.83
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-06 | 2025-08-14 | 2025-05-01 | 2025-03-27 | 2024-11-14 | 2024-08-01 | 2024-05-02 | 2024-02-29 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.13 | -0.12 | -0.14 | -0.24 | -0.27 | -0.37 | -0.33 | -0.42 | -0.37 | -0.41 | -0.65 | -0.5 |
| Estimated EPS | -0.13 | -0.1316 | -0.15 | -0.24 | -0.2825 | -0.32 | -0.42 | -0.41 | -0.45 | -0.57 | -0.52 | -0.52 |
| Surprise | 0 | 0.0116 | 0.01 | 0 | 0.0125 | -0.05 | 0.09 | -0.01 | 0.08 | 0.16 | -0.13 | 0.02 |
| Surprise Percentage | 0% | 8.8146% | 6.6667% | 0% | 4.4248% | -15.625% | 21.4286% | -2.439% | 17.7778% | 28.0702% | -25% | 3.8462% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.14 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: STTK
2026-06-12 00:40:42
Director Clay Siegall purchased 62,500 shares of Shattuck Labs Inc (STTK) on June 9, 2026, increasing his total holdings to 318,608 shares. This insider buying reflects confidence in the clinical-stage biotechnology company, despite its stock being considered "Significantly Overvalued" by GuruFocus. The transaction is part of mixed insider sentiment, with three buys and two sells over the past year.
2026-06-12 00:40:41
Redmile Group, LLC and its affiliated entities have updated their Schedule 13D filing for Shattuck Labs, Inc. (STTK), reporting a beneficial ownership of 9.9% of common stock, totaling 9,819,084 shares. This update includes details on significant warrant activity in June 2026, where Redmile funds exercised both common and pre-funded warrants and acquired additional pre-funded warrants in an underwritten offering. The filing underscores Redmile's substantial interest and recent investment maneuvers in Shattuck Labs.
2026-06-11 21:00:01
Shattuck Labs director Clay B. Siegall purchased 62,500 shares of the company's common stock at $4.00 per share in an open-market transaction. This transaction increased his direct holdings to 318,608 shares and was part of an underwritten offering that closed on June 11, 2026. The purchase, reported via a Form 4 filing, signals a positive sentiment from the insider regarding the company's prospects.
2026-06-11 12:40:01
Shattuck Labs (STTK) has announced an underwritten public equity offering, signing an agreement with Leerink Partners, J.P. Morgan Securities, Piper Sandler, and Cantor Fitzgerald. The offering includes 10.9 million common shares at $4.00 each and 7.9 million pre-funded warrants at $3.9999 each. The underwriters also exercised an option for 2.8 million additional shares, with the offering expected to close on June 11, 2026.
2026-06-11 12:40:01
Shattuck Labs, Inc. (NASDAQ: STTK) has launched a public offering of 10,879,376 shares of common stock at $4.00 per share, alongside pre-funded warrants for 7,870,624 shares at $3.9999 per warrant. The company also announced that the underwriters have fully exercised their 30-day option to purchase an additional 2,812,500 shares. This offering is being conducted under an existing shelf registration statement and is expected to close on June 11, 2026.
2026-06-10 22:39:23
Shattuck Labs announced a public offering priced at $4.00 per share, aiming to raise approximately $75 million, which is causing volatility in its stock. Despite being oversold with an RSI of 28.23 and trading below its 20-day and 50-day SMAs, the stock has shown a significant 280.17% gain over the past 12 months. The offering is expected to close on June 11, 2026.
